Key Takeaways

• Dermatologist Muneeb Shah’s skincare brand, Remedy, secured $20 million in Series A funding led by L Catterton.
• Remedy has been profitable since its first year and is projected to reach $50 million in sales this year.
• The brand leverages Shah’s significant social media presence and focuses on clinically grounded, affordable skincare products.

Remedy Secures Major Funding Round

Remedy, the skincare brand founded by dermatologist Muneeb Shah, has successfully closed a $20 million Series A funding round led by L Catterton, a significant player in consumer investing. Additional backing came from existing investor Norwest Venture Partners and new investor Sonoma Brands. Investors are particularly attracted to Remedy’s impressive performance, with projections indicating sales will hit $50 million this year, following a profitable first year.

Remedy distinguishes itself in the competitive skincare market by focusing on clinically backed products targeting the mass retail segment. Currently available at Target, the brand’s buzzworthy launch there has helped attract substantial investment interest. In addition to Target, Remedy products are sold on Amazon and TikTok Shop, with prices ranging from $25 to $35 for popular items like Remedy for Dark Spots and Remedy for Healthy Aging.

This funding round aligns with a trend in the industry where investor confidence in doctor-founded, science-backed brands continues to rise. Recent notable transactions in skincare include Bridgepoint’s $460 million acquisition of Obagi Medical and L’Oréal’s $1.1 billion investment in Medik8, reflecting a robust demand for scientifically supported skincare solutions. According to research from XRC Ventures, such brands have traded at revenue multiples significantly higher than their non-scientific counterparts over the last five years.

Shah emphasized the growing consumer demand for clinical efficacy in skincare, stating, “People want to see real efficacy. They want clinical studies.” Remedy’s brand positioning also falls under the growing “masstige” category, combining mass and prestige attributes, making it appealing to investors. Shah’s presence as a content creator enhances Remedy’s credibility, setting it apart from competitors in the space.

While the influx of investments might lead to a saturated market of skincare brands seeking exits at similar times, L Catterton’s partner Tehmina Haider highlighted Remedy as a standout brand that could shape the future of dermocosmetics.

The investment will be utilized for clinical research, product development, and enhancing organizational capabilities, aiming for a broader retail presence. Although direct-to-consumer sales currently drive most of Remedy’s revenue, there is increasing momentum in retail sales, with plans for sun care products to expand the line.

Shah stated that while there is interest from dermatology practices, Remedy does not plan to enter offices due to its pricing structure. Instead, it uses dermatologist offices as awareness channels by providing product samples. The brand also exhibited at the American Academy of Dermatology to foster relationships with professionals who can endorse its products.

Despite Shah’s broad social media reach and successful sales on TikTok Shop—over 200,000 units sold—profitability on this platform remains a challenge. He acknowledged, “I don’t really know any brands that are first-order profitable, especially at our price point.”

Shah remains optimistic about TikTok’s impact, believing in its “halo effect” that can generate consumer interest and repurchase opportunities. With Remedy set to grow, the brand aims to address various skincare needs while staying true to its commitment to clinical integrity.

The content above is a summary. For more details, see the source article.